NEUROMETRIX, INC. (NASDAQ:NURO) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws;
Change in Fiscal Year.
Certificate of Amendment to its Restated Certificate of
Incorporation, a copy of which is attached hereto as Exhibit 3.1
and incorporated herein by reference, with the Secretary of State
of the State of Delaware. The Certificate of Amendment, effective
as of May 11, 2017 effects a reverse stock split of the
Corporations common stock at a ratio of 1-to-8.
May 2, 2017, our stockholders approved an amendment to our
Restated Certificate of Incorporation to effect a reverse stock
split of our common stock, at a ratio in the range of 1-for-2 to
1-for-8. On May 2, 2017, the Corporations Board of Directors
selected the 1-for-8 reverse stock split ratio and authorized the
implementation of the reverse stock split.
pre-reverse split common stock will be combined and reclassified
into one share of our common stock, and our outstanding warrants
and shares of our preferred Stock will be combined and
reclassified in accordance with their respective terms. No
fractional shares will be issued in connection with the reverse
stock split. Stockholders who otherwise would be entitled to
receive a fractional share in connection with the reverse stock
split will receive a cash payment in lieu thereof.
acting as exchange agent for the reverse stock split and will
send instructions to stockholders of record regarding the
exchange of certificates for common stock.
the reverse stock split described above, a copy of which is being
filed as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated herein by reference.
|
Exhibit Number
|
Description
|
|
|
3.1
|
Certificate of Amendment of Restated Certificate of
Incorporation of NeuroMetrix, Inc. |
|
|
99.1
|
Press Release, dated May 11, 2017
|
About NEUROMETRIX, INC. (NASDAQ:NURO)
NeuroMetrix, Inc. (NeuroMetrix) is a health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians manage chronic pain, nerve diseases and sleep disorders. The Company operates through the sale of medical equipment and consumables segment. Its products are sold in the United States and selected overseas markets. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The Company’s products consist of a medical device used in conjunction with a consumable electrode or biosensor. Its products include Quell, which is a wearable device for relief of chronic intractable pain; SENSUS, which is a prescription neuro-stimulation device; DPNCheck, which is a nerve conduction test that is used to evaluate systemic neuropathies, and ADVANCE System, which is a platform for the performance of nerve conduction studies. NEUROMETRIX, INC. (NASDAQ:NURO) Recent Trading Information
NEUROMETRIX, INC. (NASDAQ:NURO) closed its last trading session up +0.01 at 4.09 with 149,039 shares trading hands.
